Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-5: Neoadjuvant mFOLFIRINOX, Pembrolizumab and SABR in (Borderline) Resectable Pancreatic Cancer
NCT06384560Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in pancreatic adenocarcinoma (PDAC), sponsored by Amsterdam University Medical Center. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06384560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384560.